Form S-8 - Securities to be offered to employees in employee benefit plans:
SEC Accession No. 0001140361-24-002340
Filing Date
2024-01-16
Accepted
2024-01-16 16:16:04
Documents
7
Effectiveness Date
2024-01-16

Document Format Files

Seq Description Document Type Size
1 S-8 ny20018157x2_s8.htm S-8 108811
2 EXHIBIT 5.1 ny20018157x2_ex5-1.htm EX-5.1 8839
3 EXHIBIT 23.2 ny20018157x2_ex23-2.htm EX-23.2 1946
4 EXHIBIT 23.3 ny20018157x2_ex23-3.htm EX-23.3 2485
5 EXHIBIT 99.1 ny20018157x2_ex99-1.htm EX-99.1 77615
6 FILING FEES TABLE ny20018157x2_ex107.htm EX-FILING FEES 26126
7 ny20018157x2_ex5-1img1.jpg GRAPHIC 151448
  Complete submission text file 0001140361-24-002340.txt   435693
Mailing Address 10531 4S COMMONS DRIVE SUITE 166-550 SAN DIEGO CA 92127
Business Address 1035 CAMBRIDGE STREET SUITE 18A CAMBRIDGE MA 02141 (212) 582-1199
Eterna Therapeutics Inc. (Filer) CIK: 0000748592 (see all company filings)

EIN.: 311103425 | State of Incorp.: DE | Fiscal Year End: 1231
Type: S-8 | Act: 33 | File No.: 333-276521 | Film No.: 24535334
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)